{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"86.0"},{"groupId":"OG001","lowerLimit":"10","upperLimit":"100","value":"93.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"Adherence is the percentage of prescribed pills taken while on therapy.","dispersionType":"Full Range","groups":[{"description":"Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.\n\nmemantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.","id":"OG000","title":"Arm I - Memantine"},{"description":"Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.\n\nplacebo: Placebo by mouth through completion of 12 weeks.","id":"OG001","title":"Arm II - Placebo"}],"paramType":"MEAN","populationDescription":"Participants who returned pill diaries.","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Adherence","type":"PRIMARY","unitOfMeasure":"percentage of prescribed pills"}